stockrow
Friday 6 November 2026
Export BOLD’s income statement to Excel — free account
Boundless Bio, Inc.
BOLD Healthcare Biotechnology
- EPS
- −51.4%
- Free cash flow
- −76.9%
- Total debt
- −6.85%
Quarter to June 2026, against a year earlier
2.45
0.04
+1.66%
Follow BOLD
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 24 | 24 | — | 0.0% | |
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| EBT | — | — | — | — | — | — | (46) | (49) | (65) | (58) | (64) | +8.2% | ||||||
| EBT margin, % | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | — | — | — | — | (46) | (49) | (65) | (58) | (64) | +8.2% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | — | — | — | — | (41.80) | (40.65) | (3.85) | (2.60) | (2.86) | (60.4%) | ||||||
| Cash flow | — | — | — | — | — | — | (36.06) | (38.53) | (3.58) | (2.09) | (2.51) | (61.3%) | ||||||
| Capex | — | — | — | — | — | — | (0.97) | (0.52) | (0.15) | (0.02) | (0.02) | (70.7%) | ||||||
| Free cash flow | — | — | — | — | — | — | (37.03) | (39.05) | (3.73) | (2.11) | (2.53) | (61.5%) | ||||||
| Book value | — | — | — | — | — | — | 60.34 | 99.12 | 8.87 | 4.41 | 2.94 | (58.2%) | ||||||
| Shares, m | — | — | — | — | — | — | 1 | 1 | 17 | 22 | 22 | +173.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | (40) | (47) | (61) | (47) | (56) | +5.6% | |||||
| Capex | — | — | — | — | — | — | (1) | (1) | (3) | (1) | 0 | (20.0%) | ||||||
| Free cash flow | — | — | — | — | — | — | (41) | (47) | (63) | (47) | (57) | +5.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | 60 | 115 | 146 | 97 | 66 | +17.2% | |||||
| Net debt | — | — | — | — | — | — | (64) | (121) | (104) | (62) | (73) | (1.1%) | ||||||
| Shareholders’ equity | — | — | — | — | — | — | 66 | 121 | 151 | 99 | 66 | +14.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | 0.00 | (47.83) | (38.87) | (32.02) | (50.56) | (32.0) pt | |||||
| ROIC | — | — | — | — | — | — | (1,221.33) | 0.00 | (99.20) | (107.52) | 0.00 | +1,113.8 pt | ||||||
| ROE | — | — | — | — | — | — | 0.00 | 47.36 | (554.86) | (46.69) | (67.86) | (46.7) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 72 | 64 | 28 | — | (37.6%) | |||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Boundless Bio, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| XBIT XBiotech Inc. | $57.0M | — (loss-making) | — (loss-making) | −93.33% (below 0%: shrinking) | n/m | +25.25% (above 0%: growing) | 0.00% | 0.00% | Compare |
| CLNN Clene Inc. | $56.4M | — (loss-making) | — (loss-making) | +273.33% (above 0%: growing) | n/m | −16.61% (below 0%: shrinking) | 71.43% | (11,333.93%) | Compare |
| XLO Xilio Therapeutics, Inc. | $55.9M | — (loss-making) | — (loss-making) | +131.22% (above 0%: growing) | n/m | −26.23% (below 0%: shrinking) | 100.00% | (18.68%) | Compare |
| CRBP Corbus Pharmaceuticals Holdings, Inc. | $55.3M | — (loss-making) | — (loss-making) | −92.09% (below 0%: shrinking) | n/m | −78.52% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| BOLD Boundless Bio, Inc. | $54.8M | — (loss-making) | — | — | n/m | −76.90% (below 0%: shrinking) | — | 0.00% | |
| RNXT RenovoRx, Inc. | $53.7M | — (loss-making) | — (loss-making) | +300.75% (above 0%: growing) | n/m | −12.69% (below 0%: shrinking) | 82.36% | (303.56%) | Compare |
| HRTX Heron Therapeutics, Inc. | $53.2M | — (loss-making) | — (loss-making) | +1.25% (above 0%: growing) | n/m | +78.75% (above 0%: growing) | 69.28% | (5.43%) | Compare |
| VRCA Verrica Pharmaceuticals Inc. | $53.1M | — (loss-making) | — (loss-making) | −53.85% (below 0%: shrinking) | n/m | +7.63% (above 0%: growing) | 85.02% | (223.42%) | Compare |
| RNTX Rein Therapeutics Inc. | $52.8M | — (loss-making) | — | — | n/m | −34.62% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $54.5M | — | — | +1.25% | — | −14.65% | 70.36% | (12.05%) |
Pay and ownership Proxy statement filed 28 April 2026
Ownership
Directors and executive officers, together
23.10%
Kristina Burow
12.10%
Entities and individuals affiliated with ARCH Venture Partners
12.00%
Entities and individuals affiliated with Fidelity
12.00%
Bayer HealthCare LLC
7.20%
Entities and individuals affiliated with Citadel Advisors LLC
6.40%
Zachary D. Hornby
5.70%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement